Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Franklin Templeton

Putnam Global Health Care Fund Class R Shares (PHSRX)

Ticker PHSRX · · Holdings as of May 31, 2026

Expense ratio
1.29%$129/yr per $10k
5-yr return
+7.5%annualized
1-yr return
+1.0%as of Dec 2024
Net assets
$1.5Ball share classes
Holdings
115

Bottom line

Is PHSRX a good fund? The bottom line

PHSRX is the Class R share class of Putnam Global Health Care Fund, an actively managed health care sector mutual fund from Franklin Templeton.

It charges 1.29% — about $129 a year on every $10,000 invested, more expensive than 73% of health care sector funds we track.

It returned +1.0% over one year, +7.5% a year over five years, +7.2% a year over ten (as of Dec 31, 2024, per its prospectus).

With $1.5 billion in net assets and 115 holdings, its largest position is Eli Lilly & Co. (13.1%) and the top 10 make up 61.1% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 67% top-holdings overlap).

What stands out

  • 5-year return beat 91% of category peers
  • No front-end sales load

What to watch

  • Expensive for its category (1.29%)
  • Concentrated: top 10 holdings are 61.1% of assets
  • 12b-1 marketing fee of 0.5% a year

Updated Nov 19, 2026

What PHSRX invests in

The fund seeks capital appreciation.

As a non-diversified fund concentrating in the health care industries, the fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that the Investment Manager, as defined below, believes have favorable investment potential. Under normal circumstances, the fund invests at least 80% of its net assets in securities of companies in the health care industries. This policy may be changed only after 60 days notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. The fund may purchase stocks of companies with stock prices that reflect a value lower than that which that Investment Manager places on the company. The Investment Manager may…

From the fund's prospectus (filed Dec 23, 2025).

PHSRX performance

Average annual total returns
1 yr5 yr10 yr
PHSRX+1.0%+7.5%+7.2%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2024

Full PHSRX performance history →

What PHSRX costs

On a $10,000 investment, PHSRX's 1.29% expense ratio costs about $129 a year. The prospectus estimates $1,556 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full PHSRX fee table →

PHSRX top 10 holdings

#Holding% of fund
1Eli Lilly & Co.13.15%
2Johnson & Johnson8.46%
3UnitedHealth Group, Inc.6.93%
4AbbVie, Inc.6.05%
5Novartis AG5.13%
6Merck & Co., Inc.4.88%
7AstraZeneca plc4.67%
8Thermo Fisher Scientific, Inc.4.50%
9Intuitive Surgical, Inc.4.04%
10Sanofi SA3.23%

Source: SEC Form N-PORT, period ended May 31, 2026

The top 10 make up 61.1% of the fund. See all top 25 holdings and asset mix →

Alternatives to PHSRX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%67% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%67% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%67% Compare
iSharesIXJ iShares Global Healthcare ETF0.38%78% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%64% Compare
SchwabSWHFX Schwab Health Care Fund0.8%64% Compare

More funds like PHSRX →

PHSRX FAQ

What is the expense ratio of PHSRX?
PHSRX's expense ratio is 1.29%, which works out to about $129 a year for every $10,000 invested. The prospectus estimates total costs of $1,556 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is PHSRX a good investment?
It depends on your goals, but the data points to: 5-year return beat 91% of category peers; no front-end sales load; expensive for its category (1.29%); concentrated: top 10 holdings are 61.1% of assets; 12b-1 marketing fee of 0.5% a year. This is general information, not personalized advice.
What does PHSRX hold?
PHSRX's largest holdings are Eli Lilly & Co. (13.1%), Johnson & Johnson (8.5%), UnitedHealth Group, Inc. (6.9%), AbbVie, Inc. (6.0%), Novartis AG (5.1%). It holds 115 positions in total as of May 31, 2026 (SEC Form N-PORT).
What is PHSRX's 5-year return?
PHSRX returned +7.5% a year over the five years ending Dec 31, 2024, and +7.2% a year over ten years. Past performance does not guarantee future results.
Does PHSRX have a sales load?
No. PHSRX has no front-end sales charge.
What is a cheaper alternative to PHSRX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 67% with PHSRX and charges 0.08%.
Who manages PHSRX?
PHSRX is offered by Franklin Templeton through Putnam Global Health Care Fund.